CABA

Cabaletta Bio, Inc.
CAPPED RATING

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc. (CABA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C- for 8 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -61.9%
Price Return 12M -52.6%
Catalyst Signal 0.00
Market Cap $239.4M
TTM Revenue N/A
Price / Sales N/A
ROE -89.5%

Historical Factor Score Progression

Held C- for 8 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C- (2.0) D (1.2) D- (0.9) C+ (2.6) C- (2.1)
2026-11-10 C+ (2.5) C- (2.0) D (1.2) D (1.3) C+ (2.6) C- (1.9)
2026-11-03 C+ (2.5) C- (2.0) D (1.2) D (1.3) C+ (2.7) C- (1.9)
2026-10-27 C+ (2.5) C- (2.0) D (1.2) D (1.5) C+ (2.6) C- (2.0)
2026-10-20 C+ (2.5) C- (2.0) D (1.2) D+ (1.6) C+ (2.6) C- (2.0)
Page 1 of 4